Jenny Lo-Ciganic, PhD
Dr. Wei-Hsuan “Jenny” Lo-Ciganic
Department of Pharmaceutical Outcomes & Policy
College of Pharmacy
P.O. Box 100496
Gainesville FL 32610
Phone (352) 273-3338
Website: Department of Pharmaceutical Outcomes & Policy profile
Assistant Professor, Department of Pharmaceutical Outcomes & Policy
Ph.D., Epidemiology, University of Pittsburgh, Pittsburgh, USA
M.S., Biostatistics, University of Pittsburgh, Pittsburgh, USA
M.S., Clinical Pharmacy, National Cheng-Kung University, Tainan, Taiwan
B.S., Pharmacy with a minor in Horticulture, National Taiwan University, Taipei, Taiwan
Dr. Lo-Ciganic is a pharmacoepidemiologist, with research interests in drug safety, medication adherence, prescription drug abuse and quality and value of prescribing, especially among vulnerable or minority populations. Her interests in patient safety and quality of care issues focus on improving and developing quality measures and prediction tools using advanced analytics (e.g., machine learning).
Prior to arriving at the University of Florida, Lo-Ciganic worked as an assistant professor at the University of Arizona College of Pharmacy from 2015-18. She was a recipient of the 2015 University of Arizona Health Science Career Development Award and 2016 American Association of Colleges of Pharmacy New Investigator Award. In 2017, Lo-Ciganic received the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Award in Health Outcomes. Recently she became the Co-Pi for the R01 project, “Using Machine Learning to Predict Problematic Opioid Use”, in two large state Medicaid programs, which has been funded by the National Institute of Drug Abuse (NIDA). Since 2015, she has been a member and co-chair of the Pharmacy Quality Alliance’s (PQA) workgroups and Quality Metrics Expert Panel to develop and improve quality measures of prescription medications.
- Lo-Ciganic W, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF. Evaluation of machine-learning algorithms for predicting opioid overdose risk among Medicare beneficiaries with opioid prescription. JAMA Netw Open. 2019;2(3):e190968. DOI:10.1001/jamanetworkopen.2019.0968.
- Lo-Ciganic W, Donohue JM, Kim JY, Krans EE, Jones B, Kelley D, James E, Jarlenski M. Trajectories of buprenorphine opioid agonist therapy during pregnancy in a large Medicaid program. Pharmacoepidemiol Drug Saf 2019; 28(1):80-89. PMID: 30192041. DOI: 10.1002/pds.4647.
- Cochran G, Lo-Ciganic W, Gellad WF, Gordon AJ, Cole E, Chang C, Lobo C, Frazier W, Zheng P, Chang, C-C, Kelley D, Donohue JM. Prescription Opioid Quality Measures Applied among Pennsylvania Medicaid Enrollees. J Manag Care Spec Pharm. 2018; 24(9):875-885. PMID: 30156454. DOI:10.18553/jmcp.2018.24.9.875.
- Frazier W, Cochran G, Lo-Ciganic W, Gellad WF, Gordon AJ, Chang CC, Donohue JM. Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA 2017; 318(8):750-752. PMID: 28829862. DOI: 10.1001/jama.2017.7818.
- Cochran G, Gordon AJ, Gellad WF, Chang C-C, Lo-Ciganic W, Lobo C(g), Cole E, Frazier W, Zheng P, Kelley D, Donohue JM. Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care. 2017; 23(5):e164-e171. PMID: 28810127.
- Lo-Ciganic W, Floden L, Lee JK, Ashbeck EL, Zhou L(g), Chinthammit C(g), Purdy AW, Kwoh CK, Patterns of analgesic use and risk of recurrent falls in patients with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthr Cartil 2017; 25(9):1390-1398. PMID: 28385483. DOI: 10.1016/j.joca.2017.03.017.
- Cochran G, Gordon AJ, Lo-Ciganic W, Gellad WF, Frazier W, Lobo C(g), Zheng P, Donohue JM. An examination of claims-based predictors of overdose from a large Medicaid program. Med Care. 2017; 55(3):291-298. PMCID: PMC5309160. DOI: 10.1097/MLR.0000000000000676.
- Gordon AJ, Lo-Ciganic W, Cochran G, Gellad WF, Cathers T, Donohue JM. Treatment quality for buprenorphine care: The pot at the end of the rainbow. [In Reply to “Measurement Quality of Buprenorphine Care”]. J Addict Med. 2016; 10(3):210-211. PMID: 27223837. DOI: 10.1097/ADM. 0000000000000210.
- Lo-Ciganic W, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Donohue JM. Associations between trajectories of buprenorphine treatment and emergency department and inpatient utilization. Addiction 2016; 111(5):892-902. PMID: 26662858. DOI: 10.1111/add.13270.
- Gordon AJ, Lo-Ciganic W, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM. Patterns and quality of buprenorphine opioid agonist treatment in a large medicaid program. J Addict Med 2015; 9(6):470-7. PMID: 26517324. DOI:10.1097/ADM.0000000000000164.
- Cochran G, Woo B, Lo-Ciganic W, Gordon AJ, Donohue JM, Gellad WF. Defining non-medical use of prescription opioids within health care claims: a systematic review. Subst Abus. 2015; 36(2):192-202.